← Back to Search

Radioisotope Therapy

Lu-DOTA-TATE + Chemotherapy + Immunotherapy for Small Cell Lung Cancer

Phase 1 & 2
Recruiting
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Presence of measurable disease (at least one target lesion) according to RECIST v1.1 assessed by conventional computed tomography (CT) scan
Participant is >= 18 years on the day of signing informed consent form
Must not have
Severe chronic or active infections (including active tuberculosis, HBV, or HCV infection) requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks before Cycle 1 Day 1
Active leptomeningeal disease or uncontrolled, untreated brain metastasis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of randomization until date of death from any cause, assessed up to 3 years (estimated final overall survival (os) analysis)
Awards & highlights

Summary

This trial will test a combination of drugs for ES-SCLC. It will check safety and how well it is tolerated.

Who is the study for?
This trial is for adults over 18 with newly diagnosed ES-SCLC who haven't had treatment yet. They need a positive PET scan showing SSTR and at least one measurable tumor lesion. People can't join if they have brain metastasis, autoimmune diseases, severe infections, recent major surgery, ECG abnormalities that pose risks, known drug hypersensitivity or are in another clinical study.Check my eligibility
What is being tested?
The study tests the safety of [177Lu]Lu-DOTA-TATE combined with carboplatin, etoposide, and tislelizumab as initial treatment for ES-SCLC. It also looks at using tislelizumab alone as ongoing maintenance therapy after the first treatments.See study design
What are the potential side effects?
[177Lu]Lu-DOTA-TATE may cause radiation-related side effects like nausea and fatigue. Tislelizumab can lead to immune-related issues such as inflammation in organs. Carboplatin and etoposide might result in low blood cell counts increasing infection risk and causing tiredness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have at least one tumor that can be measured on a CT scan.
Select...
I am 18 years old or older.
Select...
My scan shows at least one cancer spot is SSTR positive.
Select...
My cancer is confirmed as small cell lung cancer through a biopsy.
Select...
I am fully active and can carry on all my pre-disease activities without restriction.
Select...
I have not received any systemic treatment for small cell lung cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have severe infections needing strong antibiotics or antivirals recently.
Select...
I do not have untreated brain cancer spread or active spinal cord cancer.
Select...
I have heart issues that could make participating in the study unsafe.
Select...
I have been treated with drugs that target the immune system.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from date of randomization until date of death from any cause, assessed up to 3 years (estimated final overall survival (os) analysis)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from date of randomization until date of death from any cause, assessed up to 3 years (estimated final overall survival (os) analysis) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase 1b: Frequency of dose limiting toxicities (DLTs), Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs leading to treatment discontinuation
Phase ll: Overall survival (OS)
Secondary outcome measures
Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of [177Lu]Lu-DOTA-TATE
Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of [177Lu]Lu-DOTA-TATE
Incidence and severity of Adverse Events (AEs) and serious Adverse Events (SAEs) within 48 hours after [68Ga]Ga-DOTA-TATE administration
+18 more

Trial Design

8Treatment groups
Experimental Treatment
Group I: Phase II Experimental armExperimental Treatment4 Interventions
[177Lu]Lu-DOTA-TATE at recommended dose declared in phase I part in combination with carboplatin, etoposide and atezolizumab (experimental arm)
Group II: Phase II Control armExperimental Treatment4 Interventions
Carboplatin, etoposide and atezolizumab alone (control arm)
Group III: Dose Level 4 (DL4)Experimental Treatment5 Interventions
Dose Level 4 (DL4): [177Lu]Lu-DOTA-TATE 250 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 and atezolizumab 1200 mg in induction period, then [177Lu]Lu-DOTA-TATE 250 mCi plus atezolizumab 1200 mg in the maintenance period.
Group IV: Dose Level 3b (DL3b)Experimental Treatment5 Interventions
Dose Level 3b (DL3b): [177Lu]Lu-DOTA-TATE 200 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3, and atezolizumab 1200 mg in induction period, then [177Lu]Lu-DOTA-TATE 250 mCi plus atezolizumab 1200 mg in the maintenance period.
Group V: Dose Level 3a (DL3a)Experimental Treatment5 Interventions
Dose Level 3a (DL3a): [177Lu]Lu-DOTA-TATE 200 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3, and atezolizumab 1200 mg in induction period, then [177Lu]Lu-DOTA-TATE 200 mCi plus atezolizumab 1200 mg in the maintenance period.
Group VI: Dose Level 2b (DL2b)Experimental Treatment5 Interventions
Dose Level 2b (DL2b): [177Lu]Lu-DOTA-TATE 150 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 and atezolizumad 1200 mg in induction period, then [177Lu]Lu-DOTA-TATE 200 mCi plus atezolizumab 1200 in the maintenance period.
Group VII: Dose Level 2a (DL2a)Experimental Treatment5 Interventions
Dose Level 2a (DL2a): [177Lu]Lu-DOTA-TATE 150 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 and atezolizumab 1200 mg in induction period, then [177Lu]Lu-DOTA-TATE 150 mCi plus atezolizumab 1200 mg in the maintenance period.
Group VIII: Dose Level 1 (DL1)Experimental Treatment5 Interventions
Dose Level 1 (DL1): [177Lu]Lu-DOTA-TATE 100 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3, and atezolizumab 1200 mg in induction period, then [177Lu]Lu-DOTA-TATE 100 mCi plus atezolizumab 1200 mg in the maintenance period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
2017
Completed Phase 3
~5860

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,874 Previous Clinical Trials
4,199,791 Total Patients Enrolled

Media Library

[177Lu]Lu-DOTA-TATE (Radioisotope Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05142696 — Phase 1 & 2
Small Cell Lung Cancer Research Study Groups: Phase II Control arm, Phase II Experimental arm, Dose Level 2b (DL2b), Dose Level 3a (DL3a), Dose Level 3b (DL3b), Dose Level 1 (DL1), Dose Level 2a (DL2a), Dose Level 4 (DL4)
Small Cell Lung Cancer Clinical Trial 2023: [177Lu]Lu-DOTA-TATE Highlights & Side Effects. Trial Name: NCT05142696 — Phase 1 & 2
[177Lu]Lu-DOTA-TATE (Radioisotope Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05142696 — Phase 1 & 2
~55 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top